Abstract
Human pluripotent stem (hPS) cells such as human embryonic stem (hES) and induced pluripotent stem (hiPS) cells are vulnerable under single cell conditions, which hampers practical applications; yet, the mechanisms underlying this cell death remain elusive. In this paper, we demonstrate that treatment with a specific inhibitor of non-muscle myosin II (NMII), blebbistatin, enhances the survival of hPS cells under clonal density and suspension conditions, and, in combination with a synthetic matrix, supports a fully defined environment for self-renewal. Consistent with this, genetically engineered mouse embryonic stem cells lacking an isoform of NMII heavy chain (NMHCII), or hES cells expressing a short hairpin RNA to knock down NMHCII, show greater viability than controls. Moreover, NMII inhibition increases the expression of self-renewal regulators Oct3/4 and Nanog, suggesting a mechanistic connection between NMII and self-renewal. These results underscore the importance of the molecular motor, NMII, as a novel target for chemically engineering the survival and self-renewal of hPS cells.
Similar content being viewed by others
Introduction
Human pluripotent stem (hPS) cells including human embryonic stem (hES) and induced pluripotent stem (hiPS) cells are able to replicate themselves (self-renew) while retaining their ability to give rise to any type of specialized cells in the adult body (pluripotency). hPS cells are therefore promising sources for large-scale drug screenings or future cell-based therapeutics to treat diseases such as diabetes mellitus and spinal cord injuries1,2,3,4,5. Despite their potential clinical and industrial demand, the technical advance to control hPS cell growth remains hindered mainly because of underdeveloped culture methods and their low viability in clonal density or suspension conditions, which limits genetic manipulation and differentiation procedures6,7. Neurotrophins have been reported to protect hES cells from cell death through activation of Trk receptors8. More recently, a study showed a robust increase in hES cell survival by treatment with Y-27632, a chemical inhibitor of Rho-associated kinase (ROCK), at a level exceeding that of neurotrophins or other apoptosis inhibitors, although underlying mechanisms remained unclear9. There are multiple substrates regulated by ROCK10. In addition, Y-27632 affects several kinases other than ROCK, such as PRK2 and citron kinase10.
The culture environment of hPS cells comprises two major elements, culture medium and extracellular matrix (ECM) coating, the latter of which include Matrigel, a cocktail of mouse tumour-derived ECM widely used for the feeder-free culture method11,12. Compared with the rapid progress in basic studies on self-renewal, less practical advances have been made in the methods to support self-renewal of hPS cells. Although fully defined culture medium is now available13,14, because of the complexity of the structural components of ECM and insufficient accumulation of basic studies on cellular interactions of hPS cells, the development of fully characterized and simplified coating methods still remains a major challenge12.
We have previously demonstrated that non-muscle myosin II (NMII), a two-headed conventional myosin, has an essential role in the regulation of cellular interactions of hES cells, and NMII has been placed downstream of Rho-Rock signalling15. NMII has key roles in the broad ranges of basic biological functions, such as mitosis, migration and polarization conserved from unicellular organisms to humans16,17. Several studies also indicated the involvement of NMII in apoptotic processes in mammalian cells such as neural cells and fibroblasts18,19. To understand mechanisms underlying cell death in hPS cells and to find a new molecular target to engineer the survival threshold and cell growth under defined environments, we sought to determine the role of NMII for cell viability and self-renewal. We have found that pharmacological or genetic inhibition of NMII is sufficient to enhance survival of hPS cells under single cell growth conditions, and is able to increase expression levels of self-renewal regulators such as Oct3/4 and Nanog. Furthermore, with a pharmacological inhibitor of NMII, blebbistatin, we have developed novel fully defined and simplified culture conditions for self-renewal of hPS cells.
Results
NMII inhibition by blebbistatin enhances cloning efficiency
NMII heavy chain (NMHCII) has three isoforms16, of which NMHCIIA and NMHCIIB but not NMHCIIC are readily detectable in hES cells by immunoblot analysis (Fig. 1a). Immunocytochemical analysis demonstrated that both isoforms were predominantly localized to plasma membranes in the undifferentiated hPS cells, consistent with their role in cell–cell contacts (Fig. 1a). To evaluate the function of NMII in cell death of hPS cells, we used blebbistatin, a synthetic chemical compound that effectively and reversibly blocks the ATPase activity of NMII, thereby suppressing motor function20. We first tested the viability of hES and hiPS cells plated on Matrigel-coated plates in mTeSR at clonal density, which is an initial critical hurdle in the establishment of individual clonal lines. Single hiPS cells were plated in each well of Matrigel-coated 96-well plates and undifferentiated colony formation was evaluated by alkaline phosphatase (ALP) staining, as well as by immunocytochemistry, using an antibody against a pluripotency marker, Oct3/4, at 7 days after plating. Although no or only a few colonies were formed under the control condition at 7 days after plating, approximately 30% of wells contained single colonies when cells were treated with blebbistatin (0.47±0.25% for control versus 29±4.3% with blebbistatin, P<0.01) (Fig. 1b,c). Some of the colonies were selected, further expanded and determined to be pluripotent through a series of molecular and functional analyses, including detection of pluripotency markers and in vivo differentiation assays (Supplementary Fig. S1a–c). This cloning efficiency was comparable to that using Y-27632 (22±7.5%) (Fig. 1c and Supplementary Fig. S1d) as reported previously9.
Increased survival in adhesive conditions by blebbistatin
Next, we evaluated whether the cytoprotective effect of blebbistatin was detectable within a short period of time after plating. For all of the hPS cell culture experiments, cells were collected by trypsinization, and extensively triturated by rigorous pipetting to obtain single cells to be plated. Cells (1×105 cells per well, 12-well plates) grown in mTeSR were treated with or without blebbistatin at different concentrations, and viability was evaluated by direct cell counting at 24 h after plating. hiPS cells treated with blebbistatin survived in significantly higher numbers than did control cells (the highest effect was observed between 5 and 10 μM) when cultured on different substrates such as poly-D-lysine (PDL) (7.9±0.6×104 cells at 10 μM blebbistatin versus 0.5±0.26×104 cells for control, n=3, P<0.001) and Matrigel coating (8.6±0.6×104 cells at 10 μM blebbistatin versus 1.8±0.25×104 cells for control, n=3, P<0.01) (Fig. 1d,e, and Supplementary Fig. S1e–g). We also tested Y-27632 under the same conditions side by side, and found that the survival effect of blebbistatin was comparable to that of Y-27632 (7.2±1.1×104 cells at 10 μM on PDL, n=3, P<0.05) (Fig. 1d,e and Supplementary Fig. S1e). This result inversely correlated with the level of apoptosis detected by terminal deoxynucleotidyltransferase dUTP nick end labelling (TUNEL) assay. More than 70% of cells in the control condition were positive for TUNEL staining, whereas cells treated with blebbistatin exhibited significantly lower numbers of TUNEL-positive cells (73±2.5% for control versus 11±3.8% with blebbistatin, n=3, P<0.01) (Fig. 1f). This result was further confirmed by another indicator of apopotosis, cleaved caspase-3, which, by immunoblot analysis, was undetectable in blebbistatin-treated cells, indicating a reduced number of apoptotic cells after blebbistatin treatment (Fig. 1g).
Inhibition of NMII prevents cell death in suspension culture
To test whether blebbistatin is also effective on cells without cell–matrix adhesion, cells were grown in suspension culture, which is a common primary step for the generation of embryoid bodies in standard differentiation protocols. Cells were trypsinized and rigorously triturated to single cells and plated in non-conditioned human ES medium (hESm) with or without blebbistatin for 48 h. Remarkably, blebbistatin treatment increased the viability of hiPS cells to a level significantly higher than that of controls under suspension conditions (1.6±0.12×105 cells at 10 μM blebbistatin versus 0.05±0.02×105 cells, n=3, P<0.01) (Fig. 1h,i). hES cells and the other independent hiPS cell lines showed a comparable survival effect by blebbistatin (Fig. 1j and Supplementary Fig. S2a). This result was supported by TUNEL and cleaved caspase-3 assays demonstrating significantly lower levels of apoptosis in the blebbistatin treatment condition (Fig. 1k,l and Supplementary Fig. S2b). It is of note, however, that at a lower concentration, blebbistatin treatment consistently yielded higher viability than Y-27632, whereas at 10 μM, the survival effect of blebbistatin or Y-27632 was variable depending on individual cell lines (Fig. 1i,j and Supplementary Fig. S2a). Thus, blebbistatin provides an alternative strategy to protect hPS cells according to dosage and effectiveness on individual cell lines. To evaluate whether the observed effect of blebbistatin was due to the specific activity of the compound, we tested two available enantiomers of blebbistatin. As expected, an inactive form of blebbistatin, blebbistatin (+), did not show any significant effect on cell survival at 24 h after treatment, whereas an active enantiomer, blebbistatin (−), demonstrated an effect comparable to that of the racemic mixture, blebbistatin (±), which we mainly used in the study (Fig. 2a). Interestingly, ML-7, an inhibitor of myosin light chain kinase, which is involved in the regulation of myosin-mediated contractility and apoptosis in other cell types18,19, did not show a significant effect on survival (Fig. 2b and Supplementary Fig. S1h). This suggests that the function of NMII in the cell death regulation of pluripotent stem cells may be mainly controlled by ROCK through myosin light chain phosphatase10 rather than myosin light chain kinase. Consistent with this possibility, combined treatment with blebbistatin and Y-27632 at different concentrations for 24 h did not show substantial additive or synergistic effects on survival of hPS cells (Fig. 2c).
Several reports have indicated that hES cells show heterogeneous expression patterns of pluripotency markers such as Oct3/4 and Nanog, and exhibit distinct differentiation propensities21,22,23. To exclude the possibility that the cells responding to blebbistatin are biased to particular populations of hES cells such as differentiating cells, we took advantage of an hES cell reporter line, BGN01v Oct4-GFP, in which green fluorescent protein (GFP) is driven by the Oct3/4 promoter, allowing us to monitor the transcriptional activity of Oct3/4. More than 95% of reporter cells expressed GFP under the regular feeder-free culture condition, as determined by fluorescence microscopy (Fig. 2d). The reporter hES cells were cultured under suspension conditions for 24 h as described above, and subsequently evaluated by annexin-V staining to identify apoptotic cells (Fig. 2e). Cells treated with 5 μM blebbistatin demonstrated an increase in the percentage of annexin-V-negative cells (74±4% plus belbbistatin versus 38±8% in control, P<0.01), of which the percentage of GFP-positive cells was 80±7% (Fig. 2f). This suggests that the cell population that survived as a result of blebbistatin treatment was not biased to minor populations of hES cells such as differentiated cells, but rather represents the original cell population that consisted of mostly undifferentiated cells. In both control and blebbistatin-treated cells, many annexin-V-positive cells expressed no or relatively low levels of GFP as compared with annexin-negative cells, indicating that cells undergoing apoptosis may downregulate Oct3/4 transcriptional activity because of stress responses or other unknown mechanisms (Fig. 2f).
Synthetic compounds could in general affect multiple substrates besides the main target. It is therefore still possible that the effect on cell survival by blebbistatin may be mediated by unknown functions affecting molecules other than NMII. To verify that the inhibition of NMII is sufficient to enhance survival of hPS cells, we used a lentiviral vector carrying short hairpin RNA (shRNA) to knock down NMHCIIA. BGN01 cells constitutively expressing shRNA led to stable knockdown of NMHCIIA, and demonstrated significantly higher viability than control cells under suspension culture conditions (1.62±0.06×105 cells plus shRNA versus 0.4±0.05×105 cells in controls, n=3, P<0.01), further confirming the essential role of NMII for survival of hPS cells (Fig. 2g–j).
Enhanced survival of mES cells lacking NMHCIIA
To test whether the observed role of NMII in cell viability of hPS cells is also conserved in mice, we used mutant mouse embryonic stem (mES) cells in which both alleles of the NMHCIIA gene are disrupted (NMHCIIA−/A−)24 (Fig. 3a, full gels shown in Supplementary Fig. S3). The cell–cell contacts of mutant cells were severely impaired as previously reported24 (Fig. 3b). NMHCIIA−/A− mES cells exhibited significantly higher viability than the parental line (RW4) at 24 h after plating (1.3±0.3×105 cells for NMHCIIA−/A− versus 0.4±0.1×105 cells for controls, n=3, P<0.05) (Fig. 3c,d), consistent with the data using blebbistatin for hPS cells. The level of apoptosis was also determined by TUNEL assay, demonstrating considerably lower numbers of TUNEL-positive mutant cells as compared with wild-type mES cells (Fig. 3e).
To verify that the enhanced survival is due to the lack of NMHCIIA, we evaluated whether the observed phenotype can be rescued by reintroducing the NMHCIIA complementary DNA into the mutant (Fig. 3f,g). Mutant cells transfected with the GFP-tagged NMHCIIA complementary DNA exhibited reduced survival as compared with mutant cells transfected with a control GFP plasmid (0.78±0.05×105 cells plus NMHCIIA versus 1.38±0.12×105 cells transfected with a control plasmid, n=3, P<0.01), indicating that NMHCIIA is responsible for the altered survival of mES cells (Fig. 3h). We also found that blebbistatin effectively increased the viability of wild-type mES cells (1.48±0.07×105 cells plus blebbistatin versus 0.64±0.06×105 in control, n=3, P<0.05) as it did for hPS cells, whereas the compound treatment did not further enhance the survival of mutant mES cells lacking NMHCIIA (Fig. 3i). It has been suggested that the two isoforms of NMII, NMIIA and NMIIB, can have distinct functions in cell adhesion, migration and contractility24,25. We therefore evaluated whether NMIIB also has a role in the regulation of cell survival by using mutant mES cells genetically lacking NMHCIIB (NMHCIIB−/B−)26 (Fig. 3j). In contrast to the remarkable increase in the viability of NMHCIIA−/A− mES cells, the NMHCIIB mutant showed a survival rate similar to that of wild-type mES cells (0.54±0.1×105 cells versus 0.55±0.14×105 cells, n=3) (Fig. 3k,l). These results indicate that distinct regulatory mechanisms may control each isoform of NMII in the regulation of cell death of pluripotent stem cells, as is the case with cell adhesion and migration24,25, although other possibilities such as different amounts of each isoform in ES cells (81±7% NMHCIIA, 19±7% MHCIIB) need to be considered.
Mechanistic link between NMII and self-renewal regulators
We have previously identified a group of genes that were specifically enriched in the undifferentiated state of hES cells by conducting microarray analysis27. In searching the array database, we recognized that NMHCIIA transcripts were significantly enriched in the differentiated state of hES cells (Supplementary Table S1), suggesting a potential molecular link between self-renewal/differentiation programs and NMII. We therefore decided to investigate whether self-renewal regulators such as Oct3/4 and Nanog28,29,30 and NMII are mechanistically connected in hPS cells. hiPS or hES cells were grown in either mTeSR, which supports the undifferentiated state13, or non-conditioned hESm, which induces passive differentiation in the presence or absence of blebbistatin at different concentrations for 48 h31. hES cells treated with blebbistatin demonstrated elevated levels of both Oct3/4 and Nanog transcription factors in a dose-dependent manner under both medium conditions, as determined by quantitative reverse transcription–PCR and immunoblot analysis (Fig. 4a–d, full gels for Fig. 4c are shown in Supplementary Fig. S4). Expression of the other pluripotency marker gene, Rex-1, and lack of expression of differentiation-related marker genes were confirmed by the conventional PCR (Fig. 4e). Immunocytochemical analysis showed higher expression levels of Oct3/4 in cells treated with blebbistatin under differentiation conditions (Fig. 4f). We also found that Y-27632 treatment of hES cells also showed a moderate increase in the expression of Oct3/4 by immunoblot analysis (Supplementary Fig. S5). To determine whether this connection is also conserved in mice, we tested mES cells grown in the presence or absence of leukaemia inhibitory factor for 2 days. Consistent with the data from hES cells, both self-renewal regulators, Oct3/4 and Nanog, were expressed at substantially higher protein levels in NMHCIIA−/A− mES cells as compared with the parental cells under each condition (Fig. 4g,h). These data collectively suggest that NMII may function as a causal rather than as a consequential factor in the negative regulation of self-renewal in both human and mouse pluripotent stem cells. Although the underlying mechanisms are currently unknown, this connection could be mediated by the interactions between NMII and β1 integrin at focal adhesions which, in turn, activate multiple pathways, including ERK signalling, which has been implicated in differentiation of ES cells32,33. Alternatively, NMII may crosstalk with other self-renewal pathways such as transforming growth factor-β, PI3 kinase and Wnt signalling30,34 through as yet unidentified molecular trafficking mechanisms. Nevertheless, the upregulation of self-renewal regulators by inhibition of NMII may contribute to the enhanced survival of self-renewing pluripotent stem cells.
Establishment of a fully defined condition for hPS cells
We have recently reported that Y-27632 treatment enables hES cells to self-renew on PDL coating, a substrate on which hES cells do not normally grow15. Because PDL is a chemically synthesized substrate, unlike Matrigel, a mouse tumour-derived extract, we established a fully defined condition for self-renewal of hES cells using a defined medium, mTeSR15. As blebbistatin accurately replicates all of the effects of Y-27632 on both hES and iPS cells, we tested whether blebbistatin alone can fully replace Y-27632 in the defined culture condition. Blebbistatin was used at concentrations between 2.5 and 5 μM, which are the minimum concentrations sufficient for supporting self-renewal but not affecting cell–cell adhesions15. The maintenance of typical undifferentiated morphology and expression of pluripotency markers was confirmed in each line after 20 passages under this defined condition (Fig. 5a–d). hiPS or hES cells were able to self-renew on PDL at a constant growth rate comparable to that of cells treated with Y-27632 or cells grown under regular feeder-free conditions using Matrigel11 (Fig. 5e). To assess full differentiation functions in vivo, the passaged cells were subjected to teratoma assay by subcutaneous injection into severe combined immunodeficient (SCID)/beige mice. The teratoma samples were examined by histological analysis and determined to contain differentiated tissues derived from all three germ layers, such as melanocytes (ectoderm), neuronal tissue (ectoderm), bone (mesoderm), skeletal muscle (mesoderm), gastrointestinal-like mucosal epithelium with goblet cells (endoderm) and glomeruli (endoderm) (Fig. 5f). This was further validated by immunohistochemistry detecting specialized cell-specific marker proteins (Fig. 5g). These results confirmed that hES or hiPS cells grown under the defined condition with blebbistatin can self-renew for an extended period of time without compromising multidifferentiation capacities, verifying the full reversibility of the effect of blebbistatin. The cells were determined to maintain genomic integrity as evaluated by karyotyping (hiPS cells in Fig. 5h, and hES cells in Supplementary Fig. S6). It has been reported that the strong inhibition of NMII by blebbistatin at high concentrations (50–100 μM) affects cytokinesis20 (also seen at high concentrations of Y-2763210). We therefore evaluated the safety range of the concentrations of blebbistatin that does not affect cytokinesis of hPS cells. H9 hES cells were treated with blebbistatin at different concentrations (1.25–30 μM) in mTeSR and grown for 5 days. Cells were fixed and evaluated by immunocytochemistry using two antibodies, an antibody against β-actin to distinguish binucleated cells from cells undergoing normal cell division and an antibody against Oct3/4 to select undifferentiated cells. There were no abnormally binucleated cells at concentrations lower than 20 μM, whereas a minor fraction of the cells showed binucleation at 25 μM (Fig. 5i). At 30 μM, some colonies included multinucleated cells, although many of the cells still maintained a normal morphology (Fig. 5i). Nevertheless, it is important to maintain the concentrations of blebbistatin for hPS cell cultures at minimally sufficient levels to avoid any adverse effect.
Discussion
Although blebbistatin was originally discovered as a highly potent inhibitor for NMII (IC50=0.5–5 μM) without inhibiting class I, V and X myosin superfamily members20, it could affect other class II myosins of skeletal, cardiac and striated muscles in different species35. However, it is unlikely that these myosins have a major role in the cell death of hPS cells as they are not predominantly expressed in hES cells27 (Supplementary Table S2). Moreover, the data from stable knockdown of NMHCIIA in hES cells and NMHCIIA−/A− mES cells directly indicate the critical role of NMII in the regulation of cell death in pluripotent stem cells.
The upstream regulator of NMII in cell death of hPS cells remains to be determined. Future studies will primarily focus on small GTPases such as RhoA9,18,19, which controls cellular interactions in hES cells15, and Cdc42, which is implicated in the regulation of nuclear movement36. It is also possible that in addition to NMII, ROCK may regulate cell death through interacting with other molecules. For instance, a recent study demonstrated that c-Jun N-terminal kinase, a known regulator of apoptosis, can be activated by ROCK in ultraviolet B-induced apoptosis37. Involvement of such a diverse set of cell death mechanisms may explain why the survival effect of blebbistatin or Y-27632 was variable depending on individual hPS cell lines.
The use of blebbistatin could be advantageous in pinpointing NMII function over that of Y-27632, which is likely to affect numerous effector molecules downstream of ROCK10. In addition, blebbistatin is more cost-effective than Y-27632 for routine use. It has been suggested that fully reprogrammed hiPS cells can be generated in feeder-free conditions more efficiently than in traditional feeder-dependent culture conditions38. Thus, the novel culture method in our study may provide a basis to develop key technologies to efficiently derive and propagate new hiPS cell lines under fully defined conditions.
Our data unexpectedly demonstrated that NMII seems to be connected to self-renewal programs in both human and mouse pluripotent stem cells mediated by unknown mechanisms. The early embryonic lethality of NMHCIIA−/A− mutant mice (E6.5) may be caused not only by impairment in cell adhesions but also by defects in differentiation programmes24. It is also plausible that NMII may function as a part of the molecular sensing machineries to monitor the surrounding niches that undergo drastic changes at physical and molecular levels during developmental processes. Understanding how multiple core functions of pluripotent stem cells are integrated by the motor protein NMII may shed light on the mechanistic link between cell architectural regulators and self-renewal networks, both of which constitute the basis of pluripotent stem cell identity. Furthermore, our results highlight NMII as a promising target to pharmacologically engineer the survival threshold of hPS cells.
Methods
Chemicals
Blebbistatin (±) (InSolution Blebbistatin), Blebbistatin (+), Blebbistatin (−), Y-27632 (InSolution Y-27632) and ML-7 were purchased from EMD. The compounds were always kept in the dark to avoid photoinactivation. When blebbistatin was used for cell culture, the exposure to fluorescent light for live-cell imaging was minimized to prevent phototoxicity. PDL was obtained from Millipore.
Cell culture
Two independent hES cell lines, H9 (WiCell) and BGN01 (BresaGen), were examined. A hES reporter line, BGN01v Oct4-GFP (Invitrogen), which stably expresses GFP under the Oct3 promoter, was also tested. hiPS cells used in the study include iPS(Foreskin) Clone 1 (WiCell) and two independently derived hiPS cells from normal human dermal fibroblasts, which have been characterized by a series of molecular and functional assays. For the regular feeder-free culture, hES or hiPS cells were grown on Matrigel (BD Biosciences)-coated plates in a defined medium, mTeSR (StemCell Technologies). For maintenance, cells were regularly passaged by the standard method using dispase (Invitrogen) or trypsin-EDTA (Lonza). BGN01v Oct4-GFP was maintained in the medium containing hygromycin (Invitrogen) at 10 μg ml−1. For cell viability assay under the suspension condition, cells were grown in non-conditioned hES medium. hES medium (hESm) was prepared according to the following formula: DMEM/F12 (Invitrogen), 20% Knockout Serum Replacement (Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma), 1 mM L-glutamine (Invitrogen), 4 ng ml−1 basic-FGF (Invitrogen) and 0.1 mM non-essential amino acids31,39. mES cells used in the experiment include CJ7, E14, RW4 (a parental line of NMHCIIA−/A− mES cells), NMHCIIA−/A− and NMHCIIB−/B− mES cells24,26. Cells were maintained on either mitotically inactivated mouse embryonic fibroblasts or gelatin (Sigma)-coated dishes with the standard medium in the presence of leukaemia inhibitory factor at 1,400 U ml−1 (Millipore)40. For the rescue experiment using NMHCIIA−/A− mES cells, cells were transiently transfected with GFP-tagged NMHCIIA plasmid using lipofectamine 2000 (Invitrogen), and subjected to immunoblot analysis and survival assay 2 days after transfection. For microscopic or immunofluorescence analysis, cells were plated at approximately 5,000–10,000 cells cm−2.
For the defined culture, cells were plated at approximately 10,000 cells cm−2 on plates freshly coated with PDL or PDL-precoated plates (BD Bioscience) in mTeSR supplemented with 2.5–5 μM of blebbistatin or Y-27632. The medium was changed every day or every other day depending on confluency. For passaging, cells were collected by using trypsin-EDTA, neutralized by trypsin neutralizing solution (Lonza) and pelleted by centrifugation, followed by one-time washing with Hank's balanced salt solution to completely remove residual trypsin.
For the cell growth assay, hiPS or hES cells were plated at 2.5×104 cells cm−2 on plates coated with PDL or Matrigel in mTeSR in the presence of 5 μM blebbistatin or 5 μM Y-27632 (PDL) or in the absence of compounds (Matrigel). Cells were collected at the indicated time points, stained with Trypan blue and counted using a hemocytometer.
Lentiviral vector-based shRNA knockdown in hES cells
Lentiviral vector plasmids carrying a GFP reporter and shRNA sequences for human NMHCIIA were purchased from Open Biosystems. Lentiviral vectors were produced by transfecting the vector plasmids along with lentiviral packaging plasmids into 293T cells using lipofectamine 2000 (Invitrogen). After 24 h, the transfected cells were fed with fresh medium and grown for an additional 24 h. The culture supernatant containing the lentiviral vector was collected, filtered through a 0.45 μm filter syringe and added to BGN01 cells grown under feeder-free condition with 6 μg ml−1 polybrene. The fresh supernatant was also added to the cells on the following day. After 2–3 days, lentiviral vector infection was confirmed by GFP expression in cells using fluorescence microscopy. Cells were then treated with 1 μg ml−1 puromycin around 4 days after infection to selectively grow GFP-positive infected cells. GFP-positive colonies were manually picked up and further expanded in the presence of puromycin to establish individual knockdown lines. Each line was evaluated by immunoblot analysis to confirm efficient knockdown of NMHCIIA.
Clonal assay
hES or hiPS cells in mTeSR supplemented with or without blebbistatin were plated on Matrigel-coated 96-well plates at a single cell per well. Seven days after plating, cells were subjected to ALP assay using an Alkaline Phosphatase Detection Kit (Millipore) according to the manufacturer's instructions. The same cells were also evaluated by immunocytochemistry using an antibody against Oct3 (BD Bioscience).
Cell viability assay
hES or hiPS cells were collected by trypsinization, triturated by rigorous pipetting to obtain single cells and plated at 1×105 cells per well on 12-well plates coated with PDL or Matrigel in mTeSR in the presence or absence of blebbistatin or Y-27632 at various concentrations in triplicate. Dimethylsulphoxide (solvent for blebbistatin) was also added in the control condition and found to have no effect on viability. For mES cells, cells were plated under the same conditions, except for the use of gelatin coating and mES medium. After 24 h, cells were collected, trypsinized to single cells and counted using a hemocytometer. Cell counting was performed independently by two researchers to confirm the consistency. The same samples were used for TUNEL assay immediately after taking a small fraction of the sample for cell counting.
For the evaluation of cell viability under suspension culture, hES or hiPS cells were trypsinized, rigorously triturated by extensive pipetting to obtain single cells and plated at 5×105 in non-tissue culture-treated six-well plates with non-conditioned standard hESm containing blebbistatin or Y-27632 at different concentrations in triplicate. After 24 or 48 h, cells were collected with trypsinization and extensive trituration by pipetting, and the number of live cells was manually counted using a hemocytometer and Trypan blue staining. The cell survival ratio (%) represents the ratio of the number of live cells to the number of cells plated. The same samples were subjected to TUNEL assay for side-by-side comparison with data from the cell viability assay.
TUNEL assay
The samples in triplicate used for cell viability assay were immediately tested by TUNEL assay using an APO-DIRECT kit (BD Pharmingen) according to the manufacturer's protocol. The number of TUNEL (FITC) or propidium iodide (PI)-positive cells was counted using a hemocytometer under fluorescence microscopy with a ×20 objective. When necessary, FITC-labelled cells were verified using a ×40 objective to exclude nonspecific signal. At least 300 cells were evaluated per sample and counting was repeated twice. The ratio of the number of TUNEL-positive cells to the number of PI-positive cells was calculated. The representative result was shown in the figure from experiments repeated at least three times. Although flow cytometric analysis was initially attempted, because of persistent cell aggregation in suspension culture even after extensive trypsinization and trituration, we decided to switch to manual cell counting, which correlated well with the data obtained from cell viability assay.
Annexin-V binding assay
BGN01vOct4-GFP cells were subjected to cell viability assay under the suspension condition in the presence or absence of 5 μM blebbistatin as described above. Cells were collected 24 h after plating, and incubated with annexin-V conjugated with Alexa-647 (BioLegend) at room temperature for 15 min according to the manufacturer's instructions, counterstained with PI and evaluated by fluorescence microscope. Approximately 150 cells per each condition in triplicate were examined to classify the cells into four categories, GFP (+)/annexin (+), GFP (+)/annexin (−), GFP (−)/annexin (+) and GFP (−)/annexin (−).
Teratoma formation
All animal-related protocols were approved by the Institutional Animal Care and Use Committee. Cells (approximately 2×106 cells) grown under defined conditions for multiple passages with occasional freezing and thawing were subcutaneously injected into SCID/beige mice (Charles River Laboratories). After 4–8 weeks, the developed teratomas were excised, fixed in 4% paraformaldehyde or 10% formalin and subjected to histological section preparations.
Embryoid body formation
Cells were obtained using dispase or trypsin-EDTA, plated on non-tissue culture treated dishes (approximately 106 cells per well per six-well plate) in the absence of compounds, and grown in non-conditioned hES medium for 14 days. Cells were collected for protein extraction, and subjected to immunoblot.
Karyotyping
Standard G-banded karyotyping was carried out for each cell line approximately every 10–20 passages41.
Binucleation analysis
H9 cells were plated on Matrigel-coated 12-well plates at 5×104 cells per well with various concentrations of blebbistatin ranging from 1.25 to 30 μM. After 5 days, cells were fixed in 4% paraformaldehyde and subjected to immunocytochemical analysis with antibodies against β-actin (Sigma) at 1:500 dilution and Oct3 (BD Biosciences) at 1:100 dilution. 4,6-Diamidino-2-phenylindole was used to counterstain the nuclei. In some experiments, blebbistatin was removed from the culture medium after 5 days of incubation, and cells were further grown for another 3 days in the absence of blebbistatin. Approximately 200 cells per each condition in triplicate were examined using the fluorescence microscope. Cells undergoing cytokinesis, as indicated by the presence of actin staining at the centre of the cell, were excluded from counting.
Statistical analysis
Biological replicates (3–5 replicates per condition) were subjected to statistical analysis by using analysis of variance or the paired t-test. Statistical significance was shown as the probability value such as **P<0.01. Data points are shown as mean±s.d.
References
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
Reubinoff, B. E. et al. Neural progenitors from human embryonic stem cells. Nat. Biotechnol. 19, 1134–1140 (2001).
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007).
Park, I. H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877–886 (2008).
Amit, M. et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev. Biol. 227, 271–278 (2000).
Rao, M. Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues. Gene Ther. 15, 82–88 (2008).
Pyle, A. D., Lock, L. F. & Donovan, P. J. Neurotrophins mediate human embryonic stem cell survival. Nat. Biotechnol. 24, 344–350 (2006).
Watanabe, K. et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25, 681–686 (2007).
Riento, K. & Ridley, A. J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4, 446–456 (2003).
Xu, C. et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 19, 971–974 (2001).
Mallon, B. S., Park, K. Y., Chen, K. G., Hamilton, R. S. & McKay, R. D. Toward xeno-free culture of human embryonic stem cells. Int. J. Biochem. Cell Biol. 38, 1063–1075 (2006).
Ludwig, T. E. et al. Derivation of human embryonic stem cells in defined conditions. Nat. Biotechnol. 24, 185–187 (2006).
Lu, J., Hou, R., Booth, C. J., Yang, S. H. & Snyder, M. Defined culture conditions of human embryonic stem cells. Proc. Natl Acad. Sci. USA 103, 5688–5693 (2006).
Harb, N., Archer, T. K. & Sato, N. The Rho-Rock-Myosin signaling axis determines cell-cell integrity of self-renewing pluripotent stem cells. PLoS ONE 3, e3001 (2008).
Conti, M. A. & Adelstein, R. S. Nonmuscle myosin II moves in new directions. J. Cell Sci. 121, 11–18 (2008).
Matsumura, F. Regulation of myosin II during cytokinesis in higher eukaryotes. Trends Cell Biol. 15, 371–377 (2005).
Mills, J. C., Stone, N. L., Erhardt, J. & Pittman, R. N. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J. Cell Biol. 140, 627–636 (1998).
Croft, D. R. et al. Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration. J. Cell Biol. 168, 245–255 (2005).
Straight, A. F. et al. Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science 299, 1743–1747 (2003).
Enver, T. et al. Cellular differentiation hierarchies in normal and culture-adapted human embryonic stem cells. Hum. Mol. Genet. 14, 3129–3140 (2005).
Stewart, R., Stojkovic, M. & Lako, M. Mechanisms of self-renewal in human embryonic stem cells. Eur. J. Cancer 42, 1257–1272 (2006).
Hough, S. R., Laslett, A. L., Grimmond, S. B., Kolle, G. & Pera, M. F. A continuum of cell states spans pluripotency and lineage commitment in human embryonic stem cells. PLoS One 4, e7708 (2009).
Conti, M. A., Even-Ram, S., Liu, C., Yamada, K. M. & Adelstein, R. S. Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice. J. Biol. Chem. 279, 41263–41266 (2004).
Even-Ram, S. et al. Myosin IIA regulates cell motility and actomyosin-microtubule crosstalk. Nat. Cell Biol. 9, 299–309 (2007).
Tullio, A. N. et al. Nonmuscle myosin II-B is required for normal development of the mouse heart. Proc. Natl Acad. Sci. USA 94, 12407–12412 (1997).
Sato, N. et al. Molecular signature of human embryonic stem cells and its comparison with the mouse. Dev. Biol. 260, 404–413 (2003).
Nichols, J. et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379–391 (1998).
Mitsui, K. et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113, 631–642 (2003).
Jaenisch, R. & Young, R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132, 567–582 (2008).
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P. & Brivanlou, A. H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55–63 (2004).
Guo, W. & Giancotti, F. G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5, 816–826 (2004).
Smith, A. G. Embryo-derived stem cells: of mice and men. Annu. Rev. Cell Dev. Biol. 17, 435–462 (2001).
Boiani, M. & Scholer, H. R. Regulatory networks in embryo-derived pluripotent stem cells. Nat. Rev. Mol. Cell Biol. 6, 872–884 (2005).
Limouze, J., Straight, A. F., Mitchison, T. & Sellers, J. R. Specificity of blebbistatin, an inhibitor of myosin II. J. Muscle Res. Cell Motil. 25, 337–341 (2004).
Gomes, E. R., Jani, S. & Gundersen, G. G. Nuclear movement regulated by Cdc42, MRCK, myosin, and actin flow establishes MTOC polarization in migrating cells. Cell 121, 451–463 (2005).
Ongusaha, P. P. et al. Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci. Signal 1, ra14 (2008).
Chan, E. M. et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat. Biotechnol. 27, 1033–1037 (2009).
Sato, N. & Brivanlou, A. H. Microarray approach to identify the signaling network responsible for self-renewal of human embryonic stem cells. Methods Mol. Biol. 331, 267–283 (2006).
Sato, N. & Brivanlou, A. H. Manipulation of self-renewal in human embryonic stem cells through a novel pharmacological GSK-3 inhibitor. Methods Mol. Biol. 331, 115–128 (2006).
Baker, D. E. et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat. Biotechnol. 25, 207–215 (2007).
Acknowledgements
We acknowledge Hiroko Akuzawa for technical assistance and staff in the animal facility for SCID/beige mice maintenance. We also thank Susan Newbigging, Colin McKerlie and Lily Morikawa for teratoma pathology reports and Rebecca Gaulin for karyotyping analysis and reports. We are indebted to Ali Brivanlou, Ronald G. Crystal and Lorenz Studer for valuable scientific advice. N.S. is supported by UCR.
Author information
Authors and Affiliations
Contributions
A.W. and N.S. designed the study, conducted experiments, analysed the data and wrote the paper. H.S. and N.H. conducted experiments and analysed the data. M.A.C and R.S.A. generated essential materials for the study, analysed the data and wrote the paper. All authors discussed the results and commented on the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figures, Tables and Methods
Supplementary Figures S1-S6, Supplementary Tables S1-S4 and Supplementary Methods (PDF 500 kb)
Rights and permissions
About this article
Cite this article
Walker, A., Su, H., Conti, M. et al. Non-muscle myosin II regulates survival threshold of pluripotent stem cells. Nat Commun 1, 71 (2010). https://doi.org/10.1038/ncomms1074
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/ncomms1074
This article is cited by
-
DUSP6 is a memory retention feedback regulator of ERK signaling for cellular resilience of human pluripotent stem cells in response to dissociation
Scientific Reports (2023)
-
Bulk RNA sequencing analysis of developing human induced pluripotent cell-derived retinal organoids
Scientific Data (2022)
-
Soft substrate maintains stemness and pluripotent stem cell-like phenotype of human embryonic stem cells under defined culture conditions
Cytotechnology (2022)
-
Searching for new molecular markers for cells obtained from abdominal aortic aneurysm
Journal of Applied Genetics (2021)
-
Photoreceptor Outer Segment-like Structures in Long-Term 3D Retinas from Human Pluripotent Stem Cells
Scientific Reports (2017)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.